KR Health Research — Vaccines: mRNA flu, shingles & HPV

General health research

Three vaccines adults ask about: mRNA flu, shingles, and HPV

A neutral, sourced comparison of the new mRNA flu vaccine (mFLUSIVA), the shingles vaccine (Shingrix), and the HPV vaccine (Gardasil 9): what each is, where U.S. recommendations stand right now, how well each works, the tradeoffs, the alternatives, and what to ask a clinician. It is written for any adult (or parent) weighing these vaccines, and includes a general section for anyone with a cancer history or on cancer treatment.

This page is education only — not a recommendation to get or skip any vaccine. Decisions belong with you and your clinicians. Do not put personal health details in public feedback.

Last reviewed: October 18, 2026. U.S. vaccine policy is changing quickly this year; check the linked CDC and FDA pages for anything newer.

Why 2026 is unusual. In January 2026, HHS/CDC changed the childhood schedule without a vote of its advisory committee (ACIP) — including moving childhood flu vaccine to “shared clinical decision-making” and HPV to one dose. On March 16, 2026, a federal court stayed that schedule (and the newly appointed ACIP’s actions) while a lawsuit proceeds; the government has appealed. For the 2026–27 flu season, CDC says the July 2025 flu recommendations remain in effect “because of legal uncertainties.” Medical societies (for example AAFP and AAP) have also published their own guidance.

Congressional Research Service — schedule litigation (May 2026) CDC — 2026–27 flu clinical considerations

Side-by-side mRNA flu Shingles HPV Cancer treatment Questions Sources

Side-by-side comparison

	mRNA flu (mFLUSIVA)	Shingles (Shingrix)	HPV (Gardasil 9)
What it is	mRNA flu: mRNA vaccine (lipid nanoparticle) coding for 3 flu strain proteins; egg-free; yearly	Shingrix: Recombinant protein + adjuvant (non-live)	Gardasil 9: Recombinant virus-like particles, 9 HPV types (non-live)
U.S. status (Oct 2026)	mRNA flu: FDA-licensed Aug 5, 2026 for age 50+ (ages 65+ under accelerated approval). No CDC/ACIP recommendation yet.	Shingrix: FDA-licensed; CDC-recommended. Only shingles vaccine available in the U.S.	Gardasil 9: FDA-licensed ages 9–45; CDC-recommended routinely at 11–12, catch-up through 26
Who it’s recommended for	mRNA flu: Not yet in CDC guidance. AAFP lists it among preferred options for 65+ when available; an age-appropriate option at 50–64	Shingrix: All adults 50+; adults 19+ who are or will be immunosuppressed	Gardasil 9: Preteens (from age 9); everyone through 26 if not vaccinated; 27–45 by shared decision
Doses	mRNA flu: 1 dose each flu season	Shingrix: 2 doses, 2–6 months apart (1–2 months if immunosuppressed)	Gardasil 9: Federal guidance in effect: 2 doses if started at 9–14; 3 doses if started at 15+ or immunocompromised
How well it works	mRNA flu: 26.6% fewer flu cases than a standard-dose flu shot in a 40,805-person trial (50+). Not yet compared head-to-head on illness with high-dose shots in 65+	Shingrix: 97% (age 50+) and ~90% (70+) in trials; ~80% in years 6–11 after vaccination	Gardasil 9: ~97% against high-grade cervical disease from the added types (trial); 88% lower cervical cancer when vaccinated before 17 (Sweden)
Common side effects	mRNA flu: Sore arm (~63–69%), fatigue, headache, muscle aches, chills, underarm swelling — more frequent than comparison flu shots, usually ~2 days	Shingrix: Sore arm (~78%), muscle aches, fatigue, headache, shivering, fever; can limit activity for a day or two	Gardasil 9: Sore arm (~90%), swelling, redness; fainting can occur (sit 15 min)
Rare risks (label)	mRNA flu: Severe allergic reaction; GBS caution if it followed a past flu shot	Shingrix: Severe allergic reaction; small increased GBS risk (~3 extra cases per million doses, age 65+)	Gardasil 9: Severe allergic reaction; fainting
Main alternative	mRNA flu: Any licensed age-appropriate flu shot; for 65+, high-dose, adjuvanted, or recombinant (CDC-preferred)	Shingrix: No other U.S. vaccine; antivirals if shingles occurs	Gardasil 9: Cervical screening (does not prevent infection); condoms reduce but don’t eliminate risk

Figures are from FDA labels/reviews and peer-reviewed trials linked below. Trial percentages describe study populations, not an individual’s risk.

1 · mRNA flu vaccine (mFLUSIVA) vs standard flu vaccines

FDA-licensed · not yet CDC-recommended

What it is and where it stands

mFLUSIVA (Moderna, mRNA-1010) is the first FDA-approved mRNA seasonal flu vaccine, approved August 5, 2026 for adults 50 and older. It is a single shot each season, made without eggs, using the same lipid-nanoparticle mRNA approach as the COVID-19 mRNA vaccines.
Approval for 50–64 is traditional (based on preventing flu illness). For 65+ it is an accelerated approval based on antibody levels; FDA requires a randomized study versus a high-dose flu vaccine, with interim reports due from late 2027.
CDC has not issued a recommendation for it; for 2026–27 CDC kept its July 2025 flu guidance. The American Academy of Family Physicians includes it among preferred options for adults 65+ when available.
It is not approved for anyone under 50.

FDA — mFLUSIVA product page FDA — Summary Basis for Regulatory Action NIH DailyMed — mFLUSIVA label AAFP — 2026–27 flu guidance

Standard of care for flu (CDC, in effect for 2026–27)

Routine annual flu vaccination for everyone 6 months and older, using any FDA-licensed, age-appropriate vaccine.
For adults 65+, CDC preferentially recommends one of three: high-dose (Fluzone High-Dose), recombinant (Flublok), or adjuvanted (Fluad). If none is available, any age-appropriate flu vaccine is better than waiting.
Timing: September or October is ideal for most people; most adults (especially 65+) should avoid July–August vaccination because protection can wane over the season.
How well flu shots work: CDC’s U.S. network estimates have ranged from about 19% to 60% overall across the 2009–2026 seasons, depending largely on how well the vaccine matches circulating strains (2025–26 preliminary: 36%).

CDC — 2026–27 clinical considerations CDC — ACIP flu recommendations summary CDC — flu vaccine effectiveness by season

Possible advantages of the mRNA flu shot

In a Phase 3 trial of 40,805 adults 50+, it prevented 26.6% more PCR-confirmed flu illness than a licensed standard-dose flu shot (95% CI 16.7–35.4%), with similar results in 50–64 and 65+.
In adults 65+, it produced higher antibody levels than high-dose flu vaccine against all four strains tested.
Egg-free; FDA reviewers identified no vaccine-related serious safety signal across trials with more than 35,000 recipients.
For ages 50–64, CDC has no preferred product, so a better-performing option than standard dose may appeal to some people.

Cons, side effects & open questions

More short-term side effects than comparison shots: sore arm 68.7% (50–64) / 62.9% (65+), fatigue 48% / 42%, headache 42% / 34%, muscle aches 41% / 30%, chills 28% / 18%, underarm swelling 20% / 14%. Mostly mild–moderate, median ~2 days.
65+ benefit not yet proven on illness against the CDC-preferred high-dose shot; that study is ongoing.
Brand-new product: real-world safety and effectiveness data are only starting to accumulate.
No CDC recommendation yet, so availability and insurance coverage may vary — ask your pharmacy and plan.
Label cautions: severe allergic reaction to a component; Guillain-Barré syndrome within 6 weeks of a past flu shot calls for a careful decision.

Alternative options for flu

CDC — Flu and people 65+ CDC — Nasal spray flu vaccine CDC — Flu antiviral treatment

2 · Shingles vaccine (Shingrix, recombinant zoster vaccine)

FDA-licensed · CDC-recommended

What it is and standard of care

Shingles is a reactivation of the chickenpox virus (varicella-zoster) that can cause a painful rash and long-lasting nerve pain (postherpetic neuralgia, PHN). CDC estimates about 1 in 3 people in the U.S. will get shingles; risk rises sharply after 50 and with weakened immunity.
Shingrix is a non-live recombinant protein vaccine with an adjuvant. The older live vaccine (Zostavax) has not been available in the U.S. since November 2020.
CDC recommends 2 doses, 2–6 months apart, for all adults 50+ — whether or not they remember chickenpox, have had shingles before, or had Zostavax. No blood test is needed first.
CDC also recommends it for adults 19+ who are or will be immunodeficient or immunosuppressed by disease or therapy; the second dose can be given 1–2 months after the first.
Not given during an active shingles episode; there is no set wait afterward once it has resolved.

CDC — Shingles vaccine recommendations NIH DailyMed — Shingrix label

Pros

Very high trial efficacy: 97.2% against shingles in adults 50+ (ZOE-50) and 89.8% in adults 70+ (ZOE-70).
Durable: in long-term follow-up, efficacy was 79.8% in years 6–11 after vaccination and 87.7% overall through year 11; 87.5% against postherpetic neuralgia.
Non-live, so it can be used in people who are immunosuppressed (unlike the old live vaccine).

Lal et al., NEJM 2015 (ZOE-50) Cunningham et al., NEJM 2016 (ZOE-70) ZOE-LTFU final analysis, eClinicalMedicine 2025

Cons, side effects & risks

Strong short-term reactions are common: sore arm in about 78% and muscle aches in about 45% of adults 50+ in trials, plus fatigue, headache, shivering, fever, or stomach upset — often for 2–3 days. Some people miss a day of normal activity.
Guillain-Barré syndrome: FDA added a label warning in 2023 after an observational study estimated about 3 extra GBS cases per million doses in adults 65+ in the 42 days after vaccination.
Two doses are needed; the second dose often brings a similar reaction.
Contraindicated after a severe allergic reaction to a prior dose or component.

FDA — Shingrix GBS warning

Alternative options for shingles

CDC — Shingles clinical overview

3 · HPV vaccine (Gardasil 9)

FDA-licensed · CDC-recommended

What it is and standard of care

Human papillomavirus (HPV) causes most cervical cancers and many anal, throat (oropharyngeal), penile, vaginal, and vulvar cancers. Gardasil 9 is the only HPV vaccine used in the U.S.; it is non-live and covers 9 HPV types.
CDC recommends routine vaccination at 11–12 (can start at 9) and catch-up for everyone through 26. For 27–45, vaccination is a shared clinical decision — less benefit, because many adults have already been exposed. FDA licensure covers ages 9–45.
Doses under the federal guidance now in effect: 2 doses (0, 6–12 months) if started at 9–14; 3 doses (0, 1–2, 6 months) if started at 15+ or if immunocompromised.
One-dose debate: WHO (2022) allows a single dose for ages 9–20, based on trials such as KEN SHE. HHS/CDC moved to one dose for children in January 2026, but that schedule is stayed by a federal court while litigation continues.
The vaccine prevents new infections; it does not treat existing HPV infection or disease.

CDC — HPV vaccine recommendations NCI — HPV vaccines fact sheet WHO — single-dose update (2022)

Pros

In a randomized trial of women 16–26, Gardasil 9 was 97.4% effective against high-grade cervical, vulvar, and vaginal disease caused by the five added HPV types.
Real-world cancer prevention: in a Swedish national study, women vaccinated before age 17 had 88% lower invasive cervical cancer incidence than unvaccinated women.
One dose prevented persistent HPV 16/18 infection with 97.5% efficacy at 18 months in Kenyan women 15–20 (KEN SHE).
Non-live; can be given to people who are immunocompromised (3-dose schedule).

Huh et al., Lancet 2017 (Gardasil 9 final efficacy) Lei et al., NEJM 2020 (Sweden) Barnabas et al., NEJM Evidence 2022 (KEN SHE)

Cons, side effects & limits

Sore arm in about 90% of trial participants, swelling in about 40–48%, redness about 34%; headache and fever also reported.
Fainting can occur after the shot (mostly in adolescents); the label advises sitting or lying down and being observed for 15 minutes.
Benefit is much smaller after HPV exposure — usually lower in adults over 26.
Does not replace cervical cancer screening, and does not cover every cancer-causing HPV type.

Gardasil 9 prescribing information (FDA label)

Alternative options for HPV

USPSTF — cervical cancer screening

General considerations: a cancer history, hormone therapy, or radiation

General guidance from CDC and the Infectious Diseases Society of America (IDSA) that applies to anyone who has had cancer or is in treatment. Timing should be individualized with the treating team.

All three vaccines are non-live, so none is ruled out simply because of cancer or its treatment. Live vaccines — including the nasal-spray flu vaccine — are generally avoided in people who are immunosuppressed.
Flu: people with cancer are at higher risk of flu complications; CDC advises a flu shot (not nasal spray). IDSA guidance favors vaccinating about 2 weeks before chemotherapy when possible, though vaccinating during treatment is acceptable. Household members getting vaccinated adds protection.
Shingles: CDC recommends Shingrix from age 19 for anyone who is or will be immunosuppressed, ideally before immunosuppressive therapy starts.
HPV: immunocompromised people through 26 should get 3 doses; after 26, discuss whether there is meaningful benefit for you.
Hormone (endocrine) therapy and localized radiation affect the body differently from chemotherapy. Anyone on these treatments can ask whether their treatment counts as immunosuppressive for vaccine timing or dose schedules.
The immune response may be weaker during active immunosuppressive treatment; the treating team may advise on timing or repeating doses.

CDC — Flu and cancer IDSA — vaccines in immunocompromised patients (2026) CDC — Altered immunocompetence

Questions to ask a clinician

Given my age and health, which flu vaccine do you recommend this season — and why that one over the mRNA option (or vice versa)?
If I’m 65+, how does the mRNA flu shot compare with the high-dose, adjuvanted, or recombinant shots you already stock? Is my insurance covering it without a CDC recommendation?
Is my current treatment (chemotherapy, hormone therapy, radiation, or other) considered immunosuppressive for vaccine purposes? Should I time any vaccine around it?
Have I completed both Shingrix doses? If I’m starting a new treatment, should I compress the schedule?
Could I have a history (such as Guillain-Barré syndrome or a severe vaccine reaction) that changes which vaccine is right for me?
For HPV: does vaccination still make sense at my age, and how many doses would you give? For a child or teen: which schedule does this clinic follow right now?
Can these vaccines be given on the same day, and would that make side effects harder to manage?
What side effects should prompt a call, and how do I report one to VAERS?

Reputable sources used on this page

FDA — mFLUSIVAApproval letter, label, reviews (Aug 2026) CDC — Flu vaccine guidance 2026–27Who, which product, timing CDC — Shingles vaccineACIP-based recommendations CDC — HPV vaccineAges, doses, shared decisions NCI — HPV vaccinesCancer-prevention evidence WHO — HPV position paper (2022)Single-dose schedule rationale CRS — 2026 schedule litigationWhat the court stay means VAERSReport a suspected vaccine reaction

Couldn’t verify (left out on purpose)

Whether insurers broadly cover mFLUSIVA this season without a CDC recommendation.
Illness-prevention results for mFLUSIVA versus CDC-preferred high-dose vaccines in 65+ (study under way; first interim report due late 2027).
Final appellate outcome of the 2026 schedule litigation, as of the review date.

Elsewhere on this site

← Health Research Site home Vaccine glossary terms Send feedback

Clinical boundary: This general health research page is educational. It is not a recommendation to receive or decline any vaccine and does not replace advice from your clinicians or pharmacist (or oncology team, if you are in cancer care). Figures are population- and trial-based; your individual benefit and risk may differ. Do not put personal health details in public feedback.